Liraglutide, dulaglutide, and semaglutide have been shown to have cardiovascular benefits, and the only other glucose-lowering agents for T2D that have been shown to have cardiovascular benefits are the SGLT-2 inhibitors empagliflozin, canagliflozin and dapagliflozin (64, 65). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.